Showing results (141-150 of 301) with videos related to
Sort By:
Pageof 31
Circulation Research|May 12, 2018
PCSK9: From Basic Science Discoveries to Clinical TrialsMichael D Shapiro, Hagai Tavori, Sergio FazioJournal of the American College of Cardiology|March 18, 2014
The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapiesAllan D Sniderman, Sotirios Tsimikas, Sergio FazioCurrent Opinion in Nephrology and Hypertension|March 9, 2013
Importance of high-density lipoprotein quality: evidence from chronic kidney diseaseValentina Kon, T Alp Ikizler, Sergio FazioCurrent Atherosclerosis Reports|February 26, 2015
Targeting PCSK9 for therapeutic gainsMichael D Shapiro, Sergio Fazio, Hagai TavoriAnnual Review of Pharmacology and Toxicology|September 30, 2020
Scavenging Reactive Lipids to Prevent Oxidative InjuryLinda S May-Zhang, Annet Kirabo, Jiansheng Huang, et al.Journal of Clinical Medicine|August 29, 2024
Correction: Ferri et al. Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review. <i>J. Clin. Med.</i> 2024, <i>13</i>, 943Nicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.Journal of Clinical Medicine|February 24, 2024
Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative ReviewNicola Ferri, Massimiliano Ruscica, Sergio Fazio, et al.Trends in Cardiovascular Medicine|June 2, 2019
The PCSK9 revolution: Current status, controversies, and future directionsBruce A Warden, Sergio Fazio, Michael D ShapiroJournal of Managed Care & Specialty Pharmacy|May 28, 2016
A Systematic Review of PCSK9 Inhibitors Alirocumab and EvolocumabMarian McDonagh, Kim Peterson, Brittany Holzhammer, et al.The Annals of Pharmacotherapy|July 26, 2019
The Role of the Clinical Pharmacist in a Preventive Cardiology PracticeBruce A Warden, Michael D Shapiro, Sergio FazioPageof 31